Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema

Hatem M Marey, Amin F EllakwaOphthalmology Department, Minoufiya University, EgyptPurpose: To compare the efficacy of intravitreal injection of bevacizumab alone or combined with intravitreal triamcinolone as the primary treatment for cases with diabetic macular edema (DME).Methods: Ninety eyes were...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marey HM, Ellakwa AF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/3f0c5fb3b7cc40809f28c6a2d9e904e3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3f0c5fb3b7cc40809f28c6a2d9e904e3
record_format	dspace
spelling	oai:doaj.org-article:3f0c5fb3b7cc40809f28c6a2d9e904e32021-12-02T06:01:18ZIntravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema1177-54671177-5483https://doaj.org/article/3f0c5fb3b7cc40809f28c6a2d9e904e32011-07-01T00:00:00Zhttp://www.dovepress.com/intravitreal-bevacizumab-alone-or-combined-with-triamcinolone-acetonid-a7940https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Hatem M Marey, Amin F EllakwaOphthalmology Department, Minoufiya University, EgyptPurpose: To compare the efficacy of intravitreal injection of bevacizumab alone or combined with intravitreal triamcinolone as the primary treatment for cases with diabetic macular edema (DME).Methods: Ninety eyes were enrolled in one of the three study arms; where intravitreal triamcinolone acetonide (IVT) was used in group I, IVT/intravitreal bevacizumab (IVT/IVB) in group II, and IVB in group III. The visual acuity (VA) and central macular thickness (CMT) were used as the outcome measures, where the results of each group were calculated and compared with the results of the other.Results: There was significant improvement in the VA in the three study groups at weeks 6 and 12; with regards to the intraocular pressure (IOP), there was significant difference at week 6 in the IVT and IVT/IVB groups, and at week 12 in IVT/IVB group, and nonsignificant difference at week 6 in the IVB group and at week 12 in IVT and IVB groups.Conclusion: From this study, we conclude that IVB is an effective drug for treatment of DME, and has a long lasting effect when compared with IVT and when compared with combined IVT/IVB; adding IVT does not affect the outcome measures except for elevating the IOP in treated patients in the early post-injection period.Keywords: visual acuity, central macular thickness, intraocular pressure, IVT, IVBMarey HMEllakwa AFDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2011, Iss default, Pp 1011-1016 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Marey HM Ellakwa AF Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema
description	Hatem M Marey, Amin F EllakwaOphthalmology Department, Minoufiya University, EgyptPurpose: To compare the efficacy of intravitreal injection of bevacizumab alone or combined with intravitreal triamcinolone as the primary treatment for cases with diabetic macular edema (DME).Methods: Ninety eyes were enrolled in one of the three study arms; where intravitreal triamcinolone acetonide (IVT) was used in group I, IVT/intravitreal bevacizumab (IVT/IVB) in group II, and IVB in group III. The visual acuity (VA) and central macular thickness (CMT) were used as the outcome measures, where the results of each group were calculated and compared with the results of the other.Results: There was significant improvement in the VA in the three study groups at weeks 6 and 12; with regards to the intraocular pressure (IOP), there was significant difference at week 6 in the IVT and IVT/IVB groups, and at week 12 in IVT/IVB group, and nonsignificant difference at week 6 in the IVB group and at week 12 in IVT and IVB groups.Conclusion: From this study, we conclude that IVB is an effective drug for treatment of DME, and has a long lasting effect when compared with IVT and when compared with combined IVT/IVB; adding IVT does not affect the outcome measures except for elevating the IOP in treated patients in the early post-injection period.Keywords: visual acuity, central macular thickness, intraocular pressure, IVT, IVB
format	article
author	Marey HM Ellakwa AF
author_facet	Marey HM Ellakwa AF
author_sort	Marey HM
title	Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema
title_short	Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema
title_full	Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema
title_fullStr	Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema
title_full_unstemmed	Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema
title_sort	intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/3f0c5fb3b7cc40809f28c6a2d9e904e3
work_keys_str_mv	AT mareyhm intravitrealbevacizumabaloneorcombinedwithtriamcinoloneacetonideastheprimarytreatmentfordiabeticmacularedema AT ellakwaaf intravitrealbevacizumabaloneorcombinedwithtriamcinoloneacetonideastheprimarytreatmentfordiabeticmacularedema
_version_	1718400105376120832

Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema

Ejemplares similares